Predictable factors for lymph node metastasis in early gastric cancer analysis of clinicopathologic factors and biological markers.
Shanghai, China. In Tumour Biol, Feb 2016
We studied the relationship between clinicopathological factors, biological markers (p53, ki67, nm23, vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), E-cadherin (E-cad), beta-catenin (b-catenin), glutathione S-transferase (GST), and topoisomerase II (Topo II)), and LNM of EGC patients by chi-square test and logistic regression analysis.
Janus-faces of NME-oncoprotein interactions.
Liverpool, United Kingdom. In Naunyn Schmiedebergs Arch Pharmacol, Feb 2015
Since the identification of Nm23 (NME1, NME/NM23 nucleoside diphosphate kinase 1) as the first non-metastatic protein, a great deal of research on members of the NME family of proteins has focused on roles in processes implicated in carcinogenesis and particularly their regulation of cellular motility and the process of metastatic spread.
NM23HI as marker of metastasis in invasive ductal breast cancer.
Indonesia. In Acta Med Indones, 2012
ROC curve showed that NM23HI expression was a strongly correlated (r=0.816) sensitive and specific metastasis marker. NM23HI expression did not show asignificant relationship with histologic degree of invasive ductal carcinoma.
SET-ting the stage for life and death.
Philadelphia, United States. In Cell, 2003
In this issue of Cell, Fan et al. identify the tumor metastasis suppressor NM23-H1 as a GzmA-activated, apoptosis-inducing DNase and the oncoprotein SET as its inhibitor.